Leadership | Board of Directors

Peter Gassner is the visionary behind Veeva, one of the world’s most successful and innovative cloud software companies. He pioneered the industry cloud category when he founded Veeva in 2007 with the belief that vertical cloud software would be the next wave of cloud innovation. Today, Veeva helps more than 1,000 life sciences companies bring new medicines and treatments to patients faster.

With more than 30 years experience at leading technology companies, Peter has been at the forefront of every major transition in enterprise software, from the mainframe at IBM Silicon Valley Lab, to client-server at PeopleSoft, the cloud at Salesforce, and industry cloud software at Veeva. He was a key visionary force behind three of the industry’s most successful enterprise application platforms: Veeva Vault, the Salesforce Platform, and PeopleTools.

Peter is an advocate for corporate social responsibility, customer success, and employee success. Driven by a belief that companies have a duty to serve society, not just shareholders, he led the effort for Veeva to become a Public Benefit Corporation (PBC). With a focus on employee rights he has taken a strong stand against non-compete agreements which restrict employees’ basic freedom to change jobs.

Through his leadership, Veeva has been widely recognized as one of the world’s top growth companies, including the Fortune Future 50, Forbes Fast Tech 25, and Fortune 100 Fastest-Growing Companies.

Peter currently serves on the board of directors of Veeva and Zoom, and served on the board of directors of Guidewire Software from 2015 to 2019. He holds a bachelor of science degree in computer science from Oregon State University.

Gordon Ritter is chairman of Veeva Systems.

Gordon Ritter is a founder and general partner of Emergence Capital. He has spent over 15 years building companies which pioneered new markets including embedded web-based interfaces, server appliances, "on demand" services for the SMB market and web-native application development. He led Emergence's first investment in the on demand leader, salesforce.com. Gordon was named to the Forbes' Midas List of the top venture capital investors in 2007, 2012, 2014, and 2015. He currently sits on numerous company boards, including Veeva, Insightly, Top Hat Monocle, High Alpha, and Textio. Prior to founding Emergence, Gordon was co-founder and CEO of Software As Service, a web services platform company he created with Marc Benioff, the chairman and CEO of salesforce.com. Software As Service is the origin of salesforce.com's Salesforce 1 platform. Prior to forming Software As Service, he was vice president of the $3 billion IBM global small business division, created as a result of IBM's acquisition of his company, Whistle Communications, in 1999. Gordon's division was responsible for partnerships with dozens of technology-enabled service companies as part of IBM's on demand computing strategy. He led IBM's launch partnership with salesforce.com. Prior to IBM, Gordon was co-founder and president of Whistle, a pioneering internet appliance and services platform for small and medium-sized businesses. Gordon has a bachelor of arts degree in economics from Princeton University.

Tim Cabral serves on the board and is the audit committee chair for ServiceTitan, Doximity, and Singlestore.

Tim was CFO of Veeva Systems from 2010 to 2020, helping the company grow from ~$10 million to over $1 billion in revenue, and through its initial public offering in 2013. He was responsible for Veeva’s finance and accounting, investor relations, employee success, and legal teams.

Prior to Veeva, Tim was a senior finance executive at PeopleSoft, running the corporate financial planning and analysis organization as well as leading an operational finance team that supported the product organizations. After leaving Peoplesoft, he founded a cloud company, Agistics.

Tim graduated with a bachelor’s degree in finance and master’s degree in business from Santa Clara University.

Mark Carges works as an advisor and board member to technology companies. He currently serves on the boards of directors for Phase One A/S and Capture One A/S. He also serves on the board of directors for Meals On Wheels of San Francisco, a non-profit organization.

He was previously chief technology officer at eBay Inc. from 2009 to 2014, and served on their leadership team since 2008, overseeing eBay Inc.’s platform strategy, as well as having overall responsibility for technology, software development, and site operations for eBay.com. Since 2017, Mark also serves as senior advisor at Generation Investment Management.

Prior to joining eBay Inc., Mark was at BEA Systems, a provider of enterprise application infrastructure software which was acquired by Oracle in 2008. During more than a decade at BEA, Mark held a variety of senior technology leadership roles, including EVP, products and general manager of the business interaction division.

He began his career at Bell Labs as one of the original architects of Tuxedo, software for constructing highly scalable transaction processing applications. Mark holds a bachelor of arts from the University of California at Berkeley and a master of science degree from New York University.

Dr. Mary Lynne Hedley is a scientist, entrepreneur, biotechnology executive and corporate director with 25 years of experience working in the life science industry. She is a Venture Partner of Third Rock Ventures and a senior fellow and strategic advisor for the Broad Institute of MIT and Harvard, a biomedical research organization. She also currently serves on the board of directors of Eli Lilly and Company, Centessa Pharmaceuticals, and Youville Place and Youville House Assisted Living Residences, a non-profit organization.

Dr. Hedley served as president and chief operating officer at TESARO, an oncology-focused pharmaceutical company she co-founded in 2010 and that was acquired by GSK in 2019. Prior to that she served as executive vice president of operations and chief scientific officer at Abraxis BioScience, Inc., a biotechnology company. She was also executive vice president of Eisai Corporation of North America following the company’s acquisition of MGI PHARMA, Inc. Before that she served in various positions at MGI PHARMA, Inc., most recently as executive vice president and chief scientific officer. Dr. Hedley also co-founded and served as the president and CEO of ZYCOS, Inc., a biotechnology company that was acquired by MGI PHARMA, Inc. in 2004.

She has previously served on the boards of directors of Helsinn Healthcare SA, Millendo Therapeutics, Inc., TESARO, Inc., bluebird bio, and Receptos, Inc., which was acquired by Celgene Corp. in August 2015.

Dr. Hedley received a bachelor of science in microbiology from Purdue University and a Ph.D. in immunology from the University of Texas, Southwestern Medical Center.

Priscilla Hung is a Senior Advisor of Guidewire Software, a provider of cloud-based software for the property and casualty (P&C) insurance industry, since January 2024. She previously held roles as president and COO, chief administrative officer, senior vice president of corporate development, vice president of operations, and vice president of corporate development, since joining the company in 2005.

Prior to Guidewire, Priscilla held several management positions at Ariba Technologies Inc., Sun Microsystems and Oracle.

Priscilla is currently a member of the boards of directors of Xerox Holdings Corporation and Ethos Technologies Inc., an insuretech serving the life insurance market. Ms. Hung previously served on the board of Vonage Holdings Corp., a publicly traded cloud communications provider, until its acquisition by Telefonaktiebolaget LM Ericsson in 2022.

Priscilla holds a master degree in industrial engineering and operations research from Cornell University.

Tina Hunt, Ph.D., is executive vice president of strategy, sector development and cloud operations at IDEXX, a global leader in pet healthcare innovation. She previously held roles as executive vice president and general manager of point of care diagnostics and worldwide operations at IDEXX and corporate vice president with a portfolio that included the VetLab, diagnostic imaging, and telemedicine businesses. As IDEXX VetLab general manager, Tina led development of market-leading veterinary diagnostic analyzers and assays for a growing and increasingly complex global market.

Prior to joining IDEXX, Tina served as vice president at Woodard Curran, where she led the firm’s litigation support practice.

Tina holds an undergraduate degree in civil engineering from Panjab Engineering College, a master degree in environmental engineering from Purdue University, an MBA from the University of Southern Maine, and a Ph.D. in environmental engineering from Purdue University.

Marshall Mohr has a background in healthcare, technology, and financial services. He was previously the executive vice president of global business services and former CFO at Intuitive, pioneers of robotic-assisted surgery. Prior to Intuitive, Marshall was vice president and CFO of Adaptec, Inc. He had previously served as an audit partner with PwC where he was the managing partner of the firm’s west region technology group and led its Silicon Valley accounting and audit advisory practice.

Marshall also serves on the board of directors of Pacific Biosciences of California, Inc., and from 2005-2022, he served on the board of directors of Plantronics, Inc. until it was acquired by HP in 2022. He received his bachelor of business administration degree in accounting and finance from Western Michigan University.

Paul Sekhri has more than 30 years’ experience in life sciences, having served in executive leadership positions at some of the world’s most widely regarded pharmaceutical companies. He is president and CEO of vTv Therapeutics, a biopharma company focused on treatments for type 1 diabetes. Most recently he served as president and CEO of eGenesis, a biotech company focused on xenotransplantation, where he remains a board member and senior advisor to the chairman. Previously, Paul served as president and CEO of Lycera, an innovative biopharmaceutical company focused on treatments for autoimmune diseases and cancer. Prior to Lycera, he was an operating partner at Highline Therapeutics, a biotech incubator launched by Versant Ventures. Paul also served as senior vice president, integrated care at Sanofi where he led the creation of innovative solutions and business models to meet patient needs. Before Sanofi, Paul led global business development and was chief strategy officer at Teva. He also served as operating partner and head, biotech ops group at TPG Biotech, the life sciences venture arm of the global private investment firm TPG, where he was responsible for a portfolio of more than 50 life sciences companies. He has held the roles of founder, president, and chief executive officer of Cerimon Pharmaceuticals; president and chief business officer of ARIAD Pharmaceuticals; and partner for healthcare investments of New Leaf Ventures. Paul spent four years at Novartis, where he held various senior positions, including senior vice president, head of global search and evaluation, business development and licensing, and global head, early commercial development, where he developed the disease area strategy, and founded the early commercial development department.

Paul has been a director on more than 30 private, public company, and non-profit boards and is currently a board member of vTv Therapeutics, eGenesis, Longboard Pharmaceuticals, Compugen, and Spring Discovery.

Paul completed post-graduate studies in clinical anatomy and neuroscience at the University of Maryland, School of Medicine, and received his bachelor of science degree in zoology from the University of Maryland.

As co-founder of Veeva and its president until 2019, Matt Wallach helped build the company into one of the most valued and trusted partners to the world’s largest pharmaceutical companies and emerging biotechs. With almost 20 years of life sciences expertise, he played a pivotal role in helping meet customers’ most pressing global requirements in developing and bringing products to market.

Prior to Veeva, Matt held leadership positions in product management, marketing, and business development at various healthcare technology companies. Earlier in his career, Matt was the general manager of the pharmaceuticals & biotechnology division at Siebel Systems, where he established the company as the market leader in Pharma CRM and clinical trial management systems (CTMS) before its acquisition by Oracle.

Matt also serves on the board of directors of HealthVerity. He received an MBA from Harvard Business School and a bachelor of arts in economics from Yale University.